News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

January 25, 2024—Gore & Associates announced FDA approval for the Excluder thoracoabdominal branch endoprosthesis (TAMBE). The device is an off-the-shelf endovascular solution for the treatment of complex aneurysmal disease involving the visceral aorta.

January 6, 2025—The FDA announced it has issued draft guidance for recommendations to support development and marketing of safe and effective artificial intelligence (AI)–enabled devices throughout the device’s Total Product Life Cycle.The FDA will hold a webinar on February 18, 2025, to discuss the draft guidance.

Study Examines Nationwide Trends in Aortic Aneurysm Admissions and Repairs. January 31, 2025—In a multicenter, retrospective review of patients admitted with intact and ruptured abdominal aortic aneurysms (AAAs), thoracic aortic aneurysms (TAAs), and thoracoabdominal aortic aneurysms (TAAAs), Conroy et al found that use of endovascular and complex endovascular techniques increased over the ...

Figure 1. The Artix Thrombectomy System includes an 8-F thin-walled sheath with a 7-F access profile, a covered funnel catheter for proximal flow restriction, the MT catheter with an expandable mechanical element, and the AX aspiration catheter for exceptional treatment flexibility and control during arterial thrombectomy procedures.

Deep Venous Disease Patient Advocacy. Moderator Suresh Vedantham, MD, asks Leslie Lake, Volunteer President of the National Blood Clot Alliance and bilateral PE survivor, about patient and physician engagement in the organization, educational and outreach initiatives in deep vein thrombosis/pulmonary embolism, how physicians can get involved in patient advocacy, and more.

October 3, 2024—Synchron recently announced positive results from the COMMAND early feasibility study, which is evaluating the safety and efficacy of the Synchron brain computer interface (BCI, called the Stentrode) in six patients over a 12-month period.. The results were presented by the COMMAND study Coprincipal Investigator Elad Levy, MD, at the 2024 Congress of Neurological Surgeons ...

January 10, 2025—Navigantis Inc. recently announced the first successful neurovascular clinical cases performed with its Vasco interventional robotic platform to treat patients with neurovascular disorders. According to the company, the neurovascular interventional robotic clinical trial …

The Serranator® PTA Serration Balloon Catheter in Practice. Dr. Bitton-Faiwiszewski shares his experience treating ATK and BTK disease in an underserved patient population, plus provides results of POBA versus Serranator in a case example.

• Malignancy/limb swelling/lymphedema. Indirect CTV is a general catch-all scan and usually is obviously abnormal or entirely normal. For example, in malignancy, there may be a large lymph node mass clearly causing venous obstruction, or in lymphedema, the scan looks absolutely normal ().• Chronic iliofemoral venous obstruction (cases in which there is a swollen leg).